Using liquid biopsies to monitor treatment in HPV-related cancers
Liquid Biopsies - a Possible Tool for Treatment Monitoring and Early Recurrence Detection in HPV-associated Diseases
This study tests if using liquid biopsies can help track treatment progress and detect any return of HPV-related cancers, like cervical and throat cancer, in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 480 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic Academic / other |
| Locations | 1 site (Olomouc) |
| Trial ID | NCT05774561 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of liquid biopsies for monitoring treatment in patients with HPV-associated cancers, including cervical cancer and oropharyngeal cancer. The study aims to identify sensitive and specific biomarkers that can help in early detection of disease recurrence. It involves both prospective and retrospective components, where fresh tumor tissues and archived samples will be analyzed. Regular liquid biopsy sampling will be conducted during follow-up to assess treatment response and recurrence risk.
Who should consider this trial
Good fit: Ideal candidates include women diagnosed with cervical cancer or high-grade cervical intraepithelial lesions, and men and women diagnosed with oropharyngeal cancer.
Not a fit: Patients who do not have HPV-associated cancers or those who are not willing to participate in the study may not benefit.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive method for early detection of cancer recurrence, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using liquid biopsies for cancer monitoring, indicating a potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent. Exclusion Criteria: No exclusion criteria are set.
Where this trial is running
Olomouc
- University Hospital Olomouc — Olomouc, Czechia (Recruiting)
Study contacts
- Study coordinator: Marian Hajduch, MD., PhD.
- Email: marian.hajduch@upol.cz
- Phone: +420 585 632 083
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.